Search research articles
Contact Us
Filters
Showing results (591-600 of 686) with videos related to
Page
of 69
Sort By:
Blood Advances
|
October 25, 2019
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma
Manali Kamdar, Hongli Li, Robert W Chen, et al.
British Journal of Haematology
|
April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704
Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.
The Lancet. Haematology
|
March 19, 2017
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Sonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
John P Leonard, Morton Coleman, Jamie Ketas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
Myron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Cancer Discovery
|
August 2, 2014
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma
David Chiron, Maurizio Di Liberto, Peter Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 17, 2008
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A Goy, S H Bernstein, B S Kahl, et al.
The American Journal of Surgical Pathology
|
November 2, 2020
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy
Aliyah R Sohani, Matthew J Maurer, Sharmila Giri, et al.
Leukemia & Lymphoma
|
April 16, 2014
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab
Rebecca L Elstrom, Jia Ruan, Paul J Christos, et al.
Journal of the National Cancer Institute
|
December 18, 2016
General Biomarker Recommendations for Lymphoma
Lisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Page
of 69
Search research articles
Search
Showing results (591-600 of 686) with videos related to
Sort By:
Page
of 69
Blood Advances
|
October 25, 2019
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma
Manali Kamdar, Hongli Li, Robert W Chen, et al.
British Journal of Haematology
|
April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704
Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.
The Lancet. Haematology
|
March 19, 2017
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Sonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
John P Leonard, Morton Coleman, Jamie Ketas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
Myron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Cancer Discovery
|
August 2, 2014
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma
David Chiron, Maurizio Di Liberto, Peter Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 17, 2008
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A Goy, S H Bernstein, B S Kahl, et al.
The American Journal of Surgical Pathology
|
November 2, 2020
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy
Aliyah R Sohani, Matthew J Maurer, Sharmila Giri, et al.
Leukemia & Lymphoma
|
April 16, 2014
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab
Rebecca L Elstrom, Jia Ruan, Paul J Christos, et al.
Journal of the National Cancer Institute
|
December 18, 2016
General Biomarker Recommendations for Lymphoma
Lisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Page
of 69